Zobrazeno 1 - 10
of 266
pro vyhledávání: '"Ornella, Garrone"'
Autor:
Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Michela Palleschi, Ugo de Giorgi, Enrico Cortesi, Agnese Fabbri, Alessandra Fabi, Ida Paris, Armando Orlandi, Giuseppe Curigliano, Carmen Criscitiello, Ornella Garrone, Gianluca Tomasello, Giuliana D’Auria, Patrizia Vici, Enrico Ricevuto, Federica Domati, Claudia Piombino, Sara Parola, Roberta Scafetta, Alessio Cirillo, Beatrice Taurelli Salimbeni, Francesca Sofia Di Lisa, Lidia Strigari, Robert Preissner, Maurizio Simmaco, Daniele Santini, Paolo Marchetti, Andrea Botticelli
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)
Abstract Abemaciclib demonstrated clinical benefit in women affected by HR+/HER2− advanced breast cancer (aBC). Drug-drug interactions (DDIs) can lead to reduced treatment efficacy or increased toxicity. This retro-prospective study aimed to evalua
Externí odkaz:
https://doaj.org/article/9f47555ab4e54af1bfb2ac3aefc63ec9
Autor:
Fausto Petrelli, Maria Antista, Lorenzo Dottorini, Alessandro Russo, Marcella Arru, Roberta Invernizzi, Mariangela Manzoni, Chiara Cremolini, Alberto Zaniboni, Ornella Garrone, Gianluca Tomasello, Michele Ghidini
Publikováno v:
Heliyon, Vol 10, Iss 17, Pp e36497- (2024)
Introduction: The molecular profile of colorectal cancer (CRC) plays a crucial role in understanding patient prognosis and treatment response. Within CRC, a distinct subgroup can be identified by the presence of the BRAF V600E mutation. This specific
Externí odkaz:
https://doaj.org/article/4eb10c4254cd437fbfa1d55b7078f35a
Autor:
Alessandro Iaculli, Michele Ghidini, Francesco Locati, Laura Chiappa, Giuseppe Nastasi, Gianpiero Fasola, Francesco Grossi, Ornella Garrone, Valeria D. Tozzi
Publikováno v:
Cancer Medicine, Vol 13, Iss 13, Pp n/a-n/a (2024)
Abstract Background Although immune checkpoint inhibitors (ICIs) show a more favorable toxicity profile than classical cytotoxic drugs, their mechanism of action is responsible for peculiar new toxicities. There is an urgent need for a multidisciplin
Externí odkaz:
https://doaj.org/article/3c99d1ef91df498b88964fa32f4845db
Autor:
Nerina Denaro, Claudia Bareggi, Barbara Galassi, Giada Beltramini, Demi Wekking, Michele Proh, Tullio Ibba, Cinzia Solinas, Ornella Garrone
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundMalnutrition, defined as weight loss and unsatisfactory nutrient intake, is very common in patients with head and neck squamous cell carcinoma (HNSCC) in either the early or palliative setting. Despite increased awareness, nutritional progr
Externí odkaz:
https://doaj.org/article/e5507015deae432ab097832d4b4c0c92
Autor:
Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Michela Palleschi, Ugo de Giorgi, Enrico Cortesi, Agnese Fabbri, Alessandra Fabi, Ida Paris, Armando Orlandi, Giuseppe Curigliano, Carmen Criscitiello, Ornella Garrone, Gianluca Tomasello, Giuliana D’Auria, Patrizia Vici, Enrico Ricevuto, Federica Domati, Claudia Piombino, Sara Parola, Roberta Scafetta, Alessio Cirillo, Beatrice Taurelli Salimbeni, Francesca Sofia Di Lisa, Lidia Strigari, Robert Preissner, Maurizio Simmaco, Daniele Santini, Paolo Marchetti, Andrea Botticelli
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/16a6bc6a49b04c55b1e7f75ad7375e59
Autor:
Fausto Petrelli, Alessandro Parisi, Gianluca Tomasello, Emanuele Mini, Marcella Arru, Alessandro Russo, Ornella Garrone, Shelize Khakoo, Raffaele Ardito, Michele Ghidini
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background In metastatic pancreatic ductal adenocarcinoma (mPDAC), first line treatment options usually include combination regimens of folinic acid, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (FOLFIRINOX or mFOLFIRINOX) or gemcitabi
Externí odkaz:
https://doaj.org/article/169cae31447544f2bd844b089e500ccf
Autor:
Daniele Generali, Rossana Berardi, Michele Caruso, Marina Cazzaniga, Ornella Garrone, Ida Minchella, Ida Paris, Carmine Pinto, Sabino De Placido
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Externí odkaz:
https://doaj.org/article/e80c2bb67e5b415a9c59556c9ff142b6
Autor:
Daniele Generali, Rossana Berardi, Michele Caruso, Marina Cazzaniga, Ornella Garrone, Ida Minchella, Ida Paris, Carmine Pinto, Sabino De Placido
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Breast cancer is a major cause of death among females. Great advances have been made in treating this disease, and aromatase inhibitors (AIs) have been recognized as the cornerstone. They are characterized by high efficacy and low toxicity. The autho
Externí odkaz:
https://doaj.org/article/85b79c44bf2a4bc88979bc2f337c12a6
Autor:
Nicla La Verde, Giovanna Damia, Ornella Garrone, Daniele Santini, Alessandra Fabi, Mariangela Ciccarese, Daniele Giulio Generali, Martina Nunzi, Elena Poletto, Elisa Ferraris, Elisabetta Cretella, Giuseppa Scandurra, Icro Meattini, Alessandro Stefano Bertolini, Luigi Cavanna, Elena Collovà, Emanuela Romagnoli, Eliana Rulli, Lorenzo Legramandi, Federica Guffanti, Annalisa Bramati, Anna Moretti, Alessandra Cassano, Patrizia Vici, Valter Torri, Gabriella Farina, PAINTER investigators
Publikováno v:
Breast Cancer Research, Vol 24, Iss 1, Pp 1-12 (2022)
Abstract Background Metastatic breast cancer (MBC) is an incurable disease and its treatment focuses on prolonging patients’ (pts) overall survival (OS) and improving their quality of life. Eribulin is a microtubule inhibitor that increases OS in p
Externí odkaz:
https://doaj.org/article/ce3620b6c9374e95a95402fd78331bff
Autor:
Fausto Petrelli, Gianluca Tomasello, Maria Chiara Parati, Antonio Ghidini, Michele Ghidini, Karen Borgonovo, Mary Cabiddu, Mara Ghilardi, Roberto Reduzzi, Donatella Gambini, Alberto Zaniboni, Giovanni Faustinelli, Ornella Garrone
Publikováno v:
Medicina, Vol 60, Iss 2, p 341 (2024)
Background and Objectives: Currently, the standard treatment for non-metastatic triple-negative breast cancer (TNBC) consists of a systemic neoadjuvant (or perioperative) anthracycline plus taxane-based chemotherapy, delivered either sequentially or
Externí odkaz:
https://doaj.org/article/447ce7c1855a4d538871ad2af9d3bfd5